Two Sigma Investments
KTTA icon

Two Sigma Investments’s Pasithea Therapeutics KTTA Stock Holding History

Two Sigma Investments’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6K Sell
21,054
-27,719
-57% -$23.2K ﹤0.01% 4518
2025
Q4 		$62.9K Buy
48,773
+13,013
+36% +$11.4K ﹤0.01% 3911
2025
Q3 		$26.2K Buy
+35,760
New +$26.1K ﹤0.01% 3583

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments's KTTA Position: Q1 2026 in Review

Two Sigma Investments reduced its Pasithea Therapeutics (KTTA) stake by 57% in Q1 2026, selling an estimated $23.2K and leaving 21,054 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4518.

Two Sigma Investments first reported a position in KTTA in Q3 2025 and has held it in 3 quarters since. The position peaked at $62.9K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Two Sigma Investments held 21,054 shares of Pasithea Therapeutics worth $15.6K as of Q1 2026.
  • Two Sigma Investments sold 27,719 Pasithea Therapeutics shares in Q1 2026, an estimated $23.2K.
  • Pasithea Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4518 holding.
  • Two Sigma Investments first reported a position in Pasithea Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Two Sigma Investments's Pasithea Therapeutics position peaked at $62.9K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.